Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 11,591 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions: N95 masks and indoor air cleaner; Device
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more

Conditions: Dystonia, Epilepsy in Children, Cerebral Palsy, Tourette Syndrome, Obsessive-Compulsive Disorder, Neurologic Disorder, Movement Disorders in Children, Movement Disorders, Deep Brain Stimulation
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Self-Management Support, COPD Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: HCV Infection
Interventions: placebo, ANA598, Peginterferon, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • San Clemente, California + 17 more

Conditions: Chronic Graft Versus Host Disease, Fasciitis
Interventions: Glasdegib; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington

Conditions: Chronic Graft-Versus-Host Disease
Interventions: LBH589, Methylprednisolone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis
Interventions: Cyclophosphamide, Fludarabine, Cyclosporine, Mycophenolate mofetil, Basiliximab; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: filgrastim, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody M195; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease
Interventions: D6-25-hydroxyvitamin D3; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Spinal Cord Injury, Hyperalgesia, Secondary, Hyperalgesic Sensations
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gynecologic Cancer
Interventions: Single digit pelvic exam; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: CerebroSpinal Fluid (CSF) Leak, Chronic Otitis Media, Otospongiosis, Otosclerosis, Pulsatile Tinnitus, Cholesteatoma
Interventions: Radiation; Radiation
Lead sponsor: Carestream Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post-acute Sequelae of SARS-CoV-2 Infection
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid-Related Disorders, Chronic Pain
Interventions: Buprenorphine, Hydromorphone, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hunter Syndrome
Interventions: idursulfase-IT, No IT treatment; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: Up to 18 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Cancer Pain, Opioid Use, Cognitive Behavior Therapy
Interventions: Cognitive Behavioral Therapy for pain; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy, Chronic Illnesses, Multiple
Interventions: DigiKnowIt News: Teen; Behavioral
Lead sponsor: Innovation Research & Training; Other
Eligibility: 12 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Disease, Risk Reduction
Interventions: Chronic Disease Risk Reduction; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Peripheral Vascular Diseases
Interventions: Administration of ERC; Biological
Lead sponsor: Medistem Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Post-Traumatic Stress Disorder, Chronic, Depressed Mood, Depressive and Anxiety Disorders, Anxiety, Depression - Major Depressive Disorder
Interventions: Cognitive Processing Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions: Pralatrexate, Romidepsin; Drug
Lead sponsor: Jennifer Amengual; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Tourette Syndrome, Chronic Vocal Tic
Interventions: Abobotulinum toxin A; Drug
Lead sponsor: Detroit Clinical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Farmington Hills, Michigan

Conditions: Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases, Lymphoma, Malignant
Interventions: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT), CNS radiation treatment for ALL with prior CNS disease patients; Drug · Other · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

A Multicenter Pediatric Deep Brain Stimulation Registry

Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Glasdegib for Chronic Graft-Versus-Host Disease

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI

Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors

Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose

Cognitive-Sensorimotor Function in Long-COVID

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Psychological Intervention Using Smartphone Technology to Alleviate Malignant Pain

Web-based Resource for Children and Adolescents About Clinical Research

Rural Chronic Disease Risk Reduction

Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia

An Interrupted Time-Series Pilot Trial of LGBTQ-Affirming Cognitive Processing Therapy for Interpersonal and Developmental Trauma

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies